All companies
Visit website
Saebo
OperatingSAEBO Inc
Biotech · Founded 2004
Leaders in Home Stroke Recovery
Post-money valuation ⓘ
$11.6M
As of Apr 2022 · from Saebo Stock 1 · pre-money + amount raised, not a traded price
Total raised
$555,421
Across 1 round since 2021
Latest share price
$0.50
Saebo Stock 1 offering price
Financials
FY2018–FY2023 · from SEC filings · hover any figure for its source$4.5M
−$992K
2018
$4.4M
−$1.2M
2019
$4.0M
−$919K
2020
$4.6M
−$766K
2021
$4.6M
−$1.1M
2022
$4.4M
−$900K
2023
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
Income statement
Revenue
$4,470,674
$4,444,270
$4,032,334
$4,567,535
$4,625,783
$4,383,247
Cost of goods sold
$1,801,561
$1,783,145
$1,585,985
$1,681,375
$1,776,306
$1,586,578
Gross margin
60%
60%
61%
63%
62%
64%
Net income
-$992,477
-$1,195,857
-$919,145
-$765,524
-$1,098,216
-$899,956
Taxes paid
$0
$0
$0
$0
$0
$0
Balance sheet
Cash
$90,733
$25,660
$256,485
$534,201
$294,910
$46,213
Accounts receivable
$344,826
$401,583
$389,263
$208,192
$245,342
$319,357
Total assets
$1,382,393
$1,371,954
$1,810,260
$2,182,601
$2,030,291
$1,824,919
Short-term debt
$957,804
$1,007,162
$816,471
$843,914
$834,323
$901,143
Long-term debt
$6,754,518
$7,975,603
$8,504,611
$9,285,857
$10,121,946
$10,795,271
Total liabilities
$7,712,322
$8,982,765
$9,321,082
$10,129,771
$10,956,269
$11,696,414
Other
Headcount
—
21
21
25
—
18
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$11.6M
post-money
Saebo Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $555.4K / $1.1MInvestors 822Post-money $11.6M
Reg CF annual-report compliance
Not required3+ reports filed & assets ≤ $10M
Filed 3 of 6 annual reports (FY2020–FY2025)
822 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 13 filings on EDGARSource: ManualCIK 0001301848Share price $0.50
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.